Abstract 2057P
Background
Aging-related deficits that eventually manifest as frailty are emerging as an important determinant for quality of life and emotional health in older patients with cancer. Prevalence of frailty in long-term prostate cancer survivors and its impact on quality of life have not been investigated so far. The objective of the current study was (I) to assess the prevalence of frailty and (II) to elucidate the relationship between frailty, quality of life and emotional health in long-term prostate cancer survivors after radical prostatectomy.
Methods
2979 prostate cancer survivors from the multicenter German Familial Prostate Cancer Database were included. Patients completed the following standardized patient-reported outcome measures of interest: frailty (Groningen Frailty Indicator, GFI), quality of life (EORTC QL2), and emotional health (anxiety/depression symptoms, PHQ-4). Chi-square tests and Wilcoxon-Mann-Whitney tests were used to detect differences of selected variables between frail and non-frail patients. Associations were assessed using multiple linear regression analysis.
Results
The patients’ mean age was 79.4 years (SD = 6.4) and mean time since radical prostatectomy was 17.4 years (SD = 3.8). 33.1% (985/2979) of patients were classified as frail (GFI ≥4). Regarding mental health and quality of life, frail patients reported more often symptoms of depression (24.0% vs. 4.0%; p<0.001) and anxiety (20.6% vs. 2.0%; p<0.001) as well as lower quality of life (M = 53.4 (SD = 19.2) vs. M = 72.7 (SD = 16.0); p<0.001) compared to non-frail patients. Frailty was significantly associated with depression (OR 1.68; CI 1.49-1.89), anxiety (OR 1.75; CI 1.55-1.97), lower quality of life (OR 0.72; CI 0.67-0.77), higher age (OR 1.04; CI 1.03-1.07), and a missing partnership (OR 1.83; CI 1.37-2.45).
Conclusions
Every third long-term prostate cancer survivor after radical prostatectomy was frail. The associations with lower quality of life and poorer mental health indicates the need for an integrated care approach including further geriatric assessment and possible interventions to improve health outcomes of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06